Early identification of anthracycline cardiomyopathy: Possibilities and implications

Archives of Disease in Childhood

Volumn 75, Issue 5, 1996, Pages 416-422

  Bu'Lock, Frances A ^a,b   Mott, Martin G ^a   Oakhill, Anthony ^a   Martin, Robin P ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Anthracycline; Cardiomyopathy; Echocardiography; Monitoring

Indexed keywords

ANTHRACYCLINE DERIVATIVE;

ARTICLE; CANCER PATIENT; CARDIOMYOPATHY; CHILD; CHILDHOOD CANCER; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029853613     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.75.5.416     Document Type: Article

References (43)

1. Mott MG. Neoplasia in childhood: 25 years of progress. Ann Oncol 1995 (in press).
2. Young RC, Ozols RF, Myers CE. The anthracycline anti-neoplastic drugs. N Engl J Med 1981;305:139-53.
3. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979;63:827-34.
4. Myers CE, McGuire WP, Liss RH , et al. Adriamycin; the role of lipid peroxidation in cardiac toxicity and tumour response. Science 1977;197:165-7.
5. Doroshow JH, Reeves J. Anthracycline enhanced oxygen radical formation in the heart. Proceedings of the American Association For Cancer Research 1980;21:266(abstr).
6. Lefrak E, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973;32: 302-14.
7. Billingham ME, Bristow MR, Glatstein E, et al. Adriamycin cardiotoxicity, endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1977;1:17-23.
8. Fajardo LF, Eltringham JR, Stewart JR. Combined cardiotoxicity of adriamycin and X-radiation. Lab Invest 1976;34: 86-96.
9. Mills BA, Roberts RW.Cyclophosphamide induced cardiomyopathy: a report of two cases and a review of the English literature. Cancer 1979;43:2223-6.
10. Braverman AC, Antin JH, Plallert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone-marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215-23.
11. Unverferth DV, Unverferth BJ, Balcerzak SP, Bashore TA, Neidhart JA. Cardiac evaluation of mitoxantrone. Cancer Treat Rep 1983;67:343-50.
12. Pratt CB, Crom DB, Wallenberg J, et al. Fatal congestive heart failure following mitoxantrone therapy in two children previously treated with doxorubicin and cisplatin. Cancer Treat Rep 1983;67:85-8.
13. Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced brast cancer. J Clin Oncol 1990;8:1806-10.
14. Bonnadonna G, Gianni L, Santoro A, et al. Drugs ten years later: epirubicin. Ann Oncol 1993;4:359-69.
15. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-9.
16. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomised trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high grade extremity soft tissue sarcoma: an analysis of prognostic factors. Cancer 1991;68:1221-9.
17. Speyer JL, Green MD, Zeleniuch-Jaquotte A, et al. ICRF permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992;10:117-27.
18. Bu'Lock FA, Gabriel HM, Oakhill A, Mott MG, Martin RP. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 1993;70:185-8.
19. Von Hoff DD, Rozencweig M, Layard MW, Slavik M, Muggia FM. Daunomycin-induced cardiomyopathy in children and adults. Am J Med 1977;62:200-8.
20. Dearth J, Osborn R, Wilson E, et al. Anthracycline-induced cardiomyopathy in children. A report of six cases. Med Pediatr Oncol 1984;12:54-8.
21. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-72.
22. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 1986;46:3722-7.
23. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607-13.
24. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dyshortening fractionunction complicating doxorubicin therapy: seven year experience using serial radionuclide angiography. Am J Med 1987;82:1109-18.
25. Mott MG, Jordan SC.Cardiotoxicity of adriamycin assessed by echocardiography. Proceedings of the 10th Meeting of Société Internationale Oncologie Pediatrique. Belgium 1978: 188 (abstr).
26. Bloom KR, Bini RM, Williams CM, Sonley MJ, Gribbin MA. Echocardiography in adriamycin cardiotoxicity. Cancer 1978;41:1265-9.
27. Colan SD, Borow KM, Neumann A. Left ventricular end-systolic wall stress-velocity of fiber shortening relation: a load independent index of myocardial contractility. J Am Coll Cardiol 1984;4:715-24.
28. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of Adriamycin therapy for childhood acute lymphoblastic leukaemia. N Eng J Med 1991;324:808-15.
29. Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978;165:823-32.
30. Minow RA, Benjamin RS, Lee ET, Gottleib JA. Adriamycin cardiomyopathy: risk factors. Cancer 1977;39:1397-402.
31. Isner JM, Ferrans VJ, Cohen, SR, et al. Clinical and morphological findings after anthracycline chemotherapy. Am J Cardiol 1983;51:1167-74.
32. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982;50:32-41.
33. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function in children measured by Doppler echocardiography: normal values and relation with growth. Br Heart J 1995;73:334-9.
34. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relationships with systolic function, symptoms and pathophysiology. Br Heart J 1995;73:340-50.
35. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:701-17.
36. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
37. Steinherz L, Steinherz P, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4-20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
38. Lewis AB, Crouse VL, Evans W, Takahashi M, Siegel SE. Recovery of left ventricular function after discontinuation of anthracycline chemotherapy in children. Pediatrics 1981; 68:67-72.
39. Saini J, Rich MW, Lyss AP. Reversibility of severe LV dysfunction due to doxorubicin cardiomyopathy; report of three cases. Ann Intern Med 1987;106:814-6.
40. Steinherz LJ, Steinherz PG, Sklar C, Wollner N, Tan C. Cardiac status of 42 patients ≥ 15 years post anthracycline therapy. Med Pediatr Oncol 1994;23:176 (abstr).
41. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and non-invasive methods of assessing Adriamycin cardiotoxic effect in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 1978;62:857-64.
42. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of cardiology committee of Children's Cancer Study Group. Pediatrics 1992;89:942-9.
43. Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994;93:433-7.